| Item |
Information |
|
Drug Groups
|
experimental |
|
Description
|
Compound with anti-depressive properties used as a mental performance enhancer.
|
| Pharmacology |
Aniracetam possesses a wide range of anxiolytic properties, which may be mediated by an interaction between cholinergic, dopaminergic and serotonergic systems. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Half Life |
1-2.5 hours |
| References |
| • |
Nakamura K, Kurasawa M: Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
[Pubmed]
|
| • |
Lawrence JJ, Brenowitz S, Trussell LO: The mechanism of action of aniracetam at synaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors: indirect and direct effects on desensitization. Mol Pharmacol. 2003 Aug;64(2):269-78.
[Pubmed]
|
|
| External Links |
|
|